APLICARE, INC. – Trademark Portfolio
Entity Type: 03
APLICARE, INC. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 4 Nice Classification classes. Currently, 5 trademarks are registered. Notable registered marks include APLICARE and ISOPROPYL ALCOHOL EXCELAP POVIDONE-IODINE. The owner is based in Meriden, CT.
550 Research Parkway
Meriden, CT 06450
Showing of trademarks Trademarks
Trademark Classifications
APLICARE, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does APLICARE, INC. have?
APLICARE, INC. has 15 U.S. trademarks filed with the USPTO. Of these, 5 registered, 3 abandoned, 7 cancelled.
What trademark classes does APLICARE, INC. file in?
APLICARE, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals), Class 21 (Housewares). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are APLICARE, INC.'s most well-known trademarks?
APLICARE, INC.'s registered trademark portfolio includes well-known marks such as APLICARE and ISOPROPYL ALCOHOL EXCELAP POVIDONE-IODINE. These are among 5 currently registered trademarks in the portfolio.
What is APLICARE, INC.'s trademark registration success rate?
APLICARE, INC. has a 33% trademark registration rate, with 5 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.